Autopsy report · NCT00712426

Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)

Cause of deathFutility Automatic label, confidence 0.9, unverified. How labels are made.

“Results of an interim analysis showed that it was unlikely that creatine was effective in slowing loss of function in early symptomatic Huntington's Disease.”

The sponsor’s own words in the registry.

Life of this trial

Registered 1 year 2 months before it started.
Ran for about 5 years 4 months before it stopped.
553 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 3
Sponsor: Massachusetts General Hospital
Sponsor type: University, hospital or other
Conditions: Huntington's Disease
Interventions: Creatine Monohydrate; Placebo
Participants: 553
Sites: 47
Countries: Australia, Canada, New Zealand, United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.